Granules India Limited today inaugurated two advanced Centres of Excellence at the Technology Research Park of IIT Hyderabad: the Ascelis Center of Excellence for Peptide Development and Characterization and the Granules Center of Excellence for Particle Engineering.The inauguration was led by Dr Krishna Prasad Chigurupati,
Granules India Limited today announced that its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), located in Hyderabad (FEI: 3030495702), has received U.S. Food and Drug Administration (FDA) approval for a product that was the subject of a Pre- Approval Inspection (PAI) conducted between
As part of its Corporate Social Responsibility (CSR) initiative, Granules India Limited, a leading pharmaceutical company based in Hyderabad in collaboration with AIG Hospitals, successfully conducted a Breast Health Screening and Awareness Camp for women police officials at the Telangana State Police Headquarters. This initiative
Granules India Limited, a vertically integrated Indian pharmaceutical company, announced today that its wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received final approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lisdexamfetamine Dimesylate Capsules in strengths
Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter ended December 31, 2024. Financial Summary (All numbers in INR Mn., except Margins) QUARTERLY CONSOLIDATED FINANCIALS Q3FY25 Q2FY25 Growth (QoQ) Q3FY24 Growth (YoY)Revenue from Operations 11,377 9,666 18% 11,556 -2%EBITDA 2,303 2,033 13% 2,505 -8%EBITDA % 20% 21% 22% PAT 1,176 972 21% 1,257 -6%PAT % 10% 10% 11% Financial and Business Summary for Q3FY25The Company voluntarily paused
Granules' Ambitious Climate Targets Span Near-Term, Long-Term, and Net-Zero Goals, Aligned with the 1.5°C PathwayGranules India Limited, a leading global pharmaceutical company, has received validation and approval from the Science Based Targets initiative (SBTi) for its near-term, long-term, and net-zero goals.These targets, aligned with the
Granules India Limited is pleased to announce that Mr. Ovais Sarmad has joined as an Advisor to the company. In this role, Mr. Sarmad will provide expert guidance on sustainability, climate policy, and environmental initiatives, helping to further Granules' commitment to integrating sustainability across its
This facility manufactures APIs & formulations of oncology and non-oncology products.Granules India Limited, announced that the Company’s Unit V facility located at Anakapally, Visakhapatnam, Andhra Pradesh, India has successfully completed the US Food and Drug Administration (FDA) inspection between 8th and 12th April 2024, resulting in zero
Granules India inaugurated and launched its packaging facility through its Granules Consumer Health (GCH) step-down subsidiary which is located in Manassas, Virginia, US. The facility is over 79,000 square feet and is equipped with packaging lines and clean rooms to package and ship prescription and
